Navigation Links
Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development

PRINCETON, N.J., July 28 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced the appointment of Daniel E. Leone as Vice President of Business Development. Mr. Leone will be responsible for Laureate's worldwide business development activities, including sales and marketing. He will be supporting the company's contract development, manufacturing, and bioprocessing business.

(Logo: )

"We are pleased to welcome Dan to Laureate's Leadership Team," said Robert J. Broeze, Ph.D., President and CEO of Laureate. "Dan is a seasoned executive with more than 20 years of experience in business development and he brings an impressive background that includes broad international business development and management experience in contract manufacturing, pharmaceuticals and specialty chemicals. His capabilities include strong leadership, and strategic and organizational skills that have produced positive results in early stage and mature businesses."

Most recently Dan served as Executive Director of Contract Manufacturing at Ben Venue Laboratories where he was responsible for Sales, Marketing and New Business Development for its parenteral contract manufacturing services business. Prior to Ben Venue, Dan was the Vice President of Business Operations at Boehringer Ingelheim Chemicals where he was responsible for Sales, Marketing, New Business Development and Supply Chain Management for its active pharmaceutical ingredients business. Prior to BI, Dan held positions of increasing responsibility at Hoechst Corporation. While at Hoechst Dan served as their Global Director, Ventures in Hoechst's Research and Technology Division where he was responsible for general management of several early stage businesses. Dan earned an MBA from Duke University and Masters and Bachelors degrees in Chemical Engineering from Manhattan College.

About Laureate Pharma

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact us at or visit

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Robert Broeze

SOURCE Laureate Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010
2. US Oncology Named 2009 Laureate by IDG Computerworld Honors Program
3. Nobel Laureates to Speak at Keystone Symposia RNA Silencing Conference
4. Laureate Pharma Honored as Emerging Life Sciences Company of the Year
5. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
6. Laureate Announces Manufacturing Agreement with Tolerx
7. Laureate Pharma to Add More Manufacturing Capacity
8. ARUP Laboratories ARUP Consult(R) Recognized as a Computerworld Honors Program Laureate
9. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
10. Laureate Pharma Reports Record Growth for 2007
11. Laureate Pharma Appoints Gary Swan as Vice President of Operations
Post Your Comments:
(Date:10/12/2015)... This report covers the global cell expansion ... applications, end-user markets and geographic segmentation. Forecasts are provided ... cell expansion market generated revenue of roughly $8.5 billion ... $9.7 billion in 2015 and $22.0 billion by 2020, ... from 2015 to 2020. This report provides: ...
(Date:10/12/2015)... Oct. 12, 2015  Patara Pharma, a clinical-stage ... inflammatory diseases and conditions, today announced the closing ... financing. Concurrent with the close of its sale ... Loan and Security Agreement with Silicon Valley Bank ... million. Patara will use the funds from the ...
(Date:10/12/2015)... ... October 12, 2015 , ... NeuMedics Inc., is a specialty biopharmaceutical company focused ... safely and chronically be administered as an eye drop, announced today it has been ... Clinic and taking place October 25th to October 28th at The Cleveland Clinic, Cleveland, ...
(Date:10/9/2015)... ANNAPOLIS, Md. , Oct. 9, 2015 ... entered into the Congressional Record her statement recognizing the ... celebrated October 11-17. IPAW is sponsored by the ... companies, and is designed to:   , Raise ... contributions of plasma donors in saving and improving lives ...
Breaking Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 Americans ... of new SCIs estimated to reach 12,500 annually, the ... California Resource Services for Independent Living (SCRS-IL) is ... California opening doors to independence ... programs and services, notably assistive technology services and education. ...
(Date:9/29/2015)... 29, 2015 News facts: ... also saving energy , Minimized design shrinks PC ... Active Mode and embedded Fujitsu PalmSecure authentication enable enterprises ... Fujitsu today shows that good things come in small ... to its enterprise desktop and mobile portfolio. Featuring workplace ...
(Date:9/28/2015)... YORK , Sept. 28, 2015  The ... respiration rate and body temperature, is an essential ... can be indicators of deterioration in a patient,s ... hospital, vital signs are typically taken during routine ... hours. If a patient deteriorates between these observation ...
Breaking Biology News(10 mins):